Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 1/2 Clinical Trial of the Novel Topoisomerase I Inhibitor PEEL-224 as a Single Agent and in Combination With Vincristine and Temozolomide in Children With Refractory, Progressive or Relapsed Solid Tumors

NCT06721689 is registered in ClinicalTrials.gov with Theodore Laetsch as lead sponsor.

NCT NCT06721689
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06721689 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 1/2 Clinical Trial of the Novel Topoisomerase I Inhibitor PEEL-224 as a Single Agent and in Combination With Vincristine and Temozolomide in Children With Refractory, Progressive or Relapsed Solid Tumors
Lead sponsor
Theodore Laetsch
Phase
Phase 1/2
Overall status
Recruiting
Start date
March 23, 2025
Completion date
April 30, 2031
Enrollment
59 (estimated)
Sites
7

Conditions

As the registry lists them; a condition with its own page is linked.

refractory neuroblastoma, refractory rhabdomyosarcoma, refractory solid tumors, relapsed neuroblastoma, relapsed rhabdomyosarcoma, relapsed solid tumors